Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Drops By 16.3%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 7,804 shares, a decline of 16.3% from the December 31st total of 9,326 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 44,684 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 44,684 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are short sold.

Institutional Trading of Lisata Therapeutics

A number of institutional investors have recently modified their holdings of the company. Cerity Partners LLC acquired a new position in shares of Lisata Therapeutics in the 2nd quarter valued at approximately $32,000. CIBC Bancorp USA Inc. bought a new position in Lisata Therapeutics during the 3rd quarter valued at $37,000. Finally, Ground Swell Capital LLC acquired a new position in Lisata Therapeutics during the 3rd quarter worth $62,000. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Analyst Upgrades and Downgrades

LSTA has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Thursday, January 22nd. Zacks Research lowered Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Finally, Brookline Capital Management downgraded Lisata Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.50.

Lisata Therapeutics Stock Down 0.2%

Shares of LSTA traded down $0.01 during mid-day trading on Monday, hitting $4.62. The company had a trading volume of 24,960 shares, compared to its average volume of 350,848. Lisata Therapeutics has a 1-year low of $1.81 and a 1-year high of $4.89. The business’s 50-day simple moving average is $2.39 and its 200-day simple moving average is $2.42. The stock has a market cap of $40.75 million, a PE ratio of -2.17 and a beta of 1.23.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. On average, sell-side analysts expect that Lisata Therapeutics will post -2.66 earnings per share for the current year.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.